What the research found

GLP-1 receptor agonists (semaglutide, tirzepatide) are labelled by the FDA as maintenance medications—their indications explicitly state they are meant to "reduce excess body weight and maintain weight reduction long term." Yet neither drug's prescribing information contains guidance on how to discontinue treatment electively or manage the transition off the drug. The word "taper" does not appear in either label. Dosage sections cover initiation, titration, switching between formulations, and dose escalation, but not planned cessation. Discontinuation instructions exist only for safety events (pancreatitis, hypersensitivity) or changed circumstances (pregnancy), not for situations where tolerability or benefit-to-burden ratio shifts during ongoing treatment.

This represents a structural gap: the clinical trial programmes that led to FDA approval were designed to demonstrate sustained weight loss on the drug, not what happens during or after planned withdrawal. The regulatory approval process captured the entry and maintenance phases thoroughly. The exit phase—common enough in real practice—was not formally studied or documented.

Why it matters for you

If you use semaglutide or tirzepatide and decide to pause or stop—whether due to side effects like nausea, cost, availability, or a planned transition to another intervention—you and your prescriber have no evidence-based protocol to follow. This creates practical problems:

During the decision. You can't refer to official guidance on what to expect if you taper versus stop abruptly. Rebound weight gain is reported anecdotally but not quantified in the label. Changes in appetite, satiety, or hunger hormones have no timeline attached. Blood glucose and metabolic markers may shift; how quickly and by how much isn't specified.

After cessation. If you track biomarkers—fasting glucose, HbA1c, lipids, body weight—you won't have a reference for normal post-discontinuation trajectories. How long satiety suppression persists, whether insulin sensitivity recovers, or whether cardiovascular benefits persist are open questions in the label itself. If you're considering restarting later (as the opening example illustrates), there's no guidance on timing or whether prior exposure changes your response.

This matters most if you're managing diabetes or metabolic syndrome alongside other interventions (diet, training, other peptides or medications). The absence of a documented exit strategy means you're essentially designing your own based on individual tolerance and clinical judgment—which is workable, but leaves real uncertainty.

Caveats

  • Regulatory, not clinical evidence. This describes what is (or isn't) in FDA-approved labels, not what clinical data exists. Some exit-phase information may exist in trial databases or literature not yet compiled into consensus guidance.
  • Snapshot in time. Labels are updated; the February 2026 versions cited here may change. The Wegovy label recently added switching instructions, suggesting the agency does update dosing sections when new use patterns emerge.
  • Anecdotal framing. The opening case is a single patient account, offered to illustrate the gap, not evidence of how common it is or what outcomes are typical.
  • Not medical advice. Decisions to pause or discontinue should involve your prescriber, not rely on label absence as justification.